Moderna, Inc. Banner Image

Moderna, Inc. has reached its limit for free report views

Work for Moderna, Inc.? Upgrade Your Profile and unlock all your annual reports.

Moderna, Inc.

  • Ticker MRNA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Moderna, Inc. Logo Image
  • 501-1000 Employees
  • Based in Cambridge, Massachusetts
Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,900 participants, prior to enrolling the Phase 3 study of mRNA-1273, have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technologyMore has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.
Moderna, Inc.

Most Recent Annual Report

Moderna, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Moderna, Inc. has reached its limit for free report views.

Older/Archived Annual Reports